Category Archives: AZBio News

Thousands of Arizonans to Contribute to 2-Year COVID-19 Study

Posted on by

Actively recruiting —

A cross-campus collaboration spearheaded by the College of Public Health seeks to understand ‘long COVID’ and other coronavirus mysteries.

After more than a year since its earliest documented appearance, much remains unknown about SARS-CoV-2. The lack of actionable data about the novel coronavirus, which threw the world into a pandemic, has prompted the University of Arizona Health Sciences to undertake the first statewide long-term public health study of COVID-19: the Arizona CoVHORT study. The research effort is intended to shed light on infection risk and the recovery process to improve care for patients touched by this crisis.

Continue reading→

Janssen Investigational COVID-19 Vaccine: Interim Analysis of Phase 3 Clinical Data Released

Posted on by

An investigational COVID-19 vaccine developed by Janssen Pharmaceuticals appears to be safe and effective at preventing moderate and severe COVID-19 in adults, according to an interim analysis of Phase 3 clinical data conducted Jan. 21. The vaccine, called Ad.26.COV2.S or JNJ-78436725, requires only a single injection and can be stored in a refrigerator for months.Continue reading→

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Posted on by
  • Vaccine Candidate 72% Effective in the US and 66% Effective Overall at Preventing Moderate to Severe COVID-19, 28 Days after Vaccination
  • 85% Effective Overall in Preventing Severe Disease and Demonstrated Complete Protection Against COVID-19 related Hospitalization and Death as of Day 28
  • Protection Against Severe Disease Across Geographies, Ages, and Multiple Virus Variants, including the SARS-CoV-2 Variant from the B.1.351 Lineage [1] Observed in South Africa
  • Single-shot compatible with standard vaccine distribution channels provides important tool in pandemic setting

[1] The B.1.351 lineage also known as 501Y.V2 variant and 20H/501Y.V2 (formerly 20C/501Y.V2) is a variant of SARS-CoV-2, the virus that causes COVID-19Continue reading→

A Better Way to Diagnose Breast Cancer?

Posted on by

TGEN-LED STUDY RESULTS SUGGEST A MORE ACCURATE DIAGNOSTIC FOR BREAST CANCER

Proteomics-based technology could help verify mammography screening

PHOENIX, Ariz. — Jan. 26, 2021 — Breast cancer, even at its initial stages, could be detected earlier and more accurately than current techniques using blood samples and a unique proteomics-based technology, according to findings of a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

Written by Steve Yozwiak

Continue reading→

Equality Health and General Atlantic Announce Strategic Partnership to Help Drive Continued Expansion of Equality’s Value-Based Primary Care Network and Technology Solutions

Posted on by

Strategic investment from General Atlantic to help enable Equality Health in furthering its mission of increasing access to care, lowering costs and improving outcomes for underserved individuals, families and communities

Equality Health to acquire actuarial firm, Daraja Services, to deepen healthcare economics capabilitiesContinue reading→

Opportunty Alert: EMERGEAZ Fast Grants

Posted on by

In partnership with the Arizona Governor’s Office, invisionAZ and StartupAZ are offering financial support to the state’s startups through the EMERGEAZ Fast Grant. Local entrepreneurs and startups with emerging technologies designed to address the impacts of the pandemic are encouraged to apply. There is a total of $1 million in the fund and grants will be awarded in amounts ranging from $25,000 to $50,000.Continue reading→